Director Dealings / Market Share Transactions

RNS Number : 8152W

Oxford Biomedica PLC

23 April 2019

 

Director Dealings / Market Share Transactions

Oxford, UK - 23 April 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, bought 2,711 ordinary shares of 50p each ("Ordinary Shares") in the Company on 23 April 2019 on the London Stock Exchange at a price of 667.8p.

3,312 Ordinary Shares were purchased by Dr. Heath's wife (Eva Lackner) on 23 April 2019 on the London Stock Exchange at a price of 672.8p and are therefore considered a beneficial holding of Dr. Heath.

Following this purchase Dr. Andrew Heath holds 50,000 shares representing 0.08% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold and purchased.

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Dr. Andrew Heath
2.	Reason for the notification
a.	Position/status	Deputy Chairman and Senior Independent Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£6.68	2,711
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	2,711  £6.6784  £18,105.14
f.	Date of the transaction	2019-04-23
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Eva Lackner
2.	Reason for the notification
a.	Position/status	Person closely associated with Dr. Andrew Heath, Deputy Chairman and Senior Independent Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£6.73	3,312
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	3,312  £6.7276  £22,281.81
f.	Date of the transaction	2019-04-23
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Company is 66,170,638 ordinary shares of 50 pence each.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Stuart Paynter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

 

END

 

 

DSHBXLFLKZFXBBZ